Abstract: Objective To study expression of annexinA5 (ANXA5) in uterine cervical squamous carcinoma of different clinical stages in order to explore the possibility of using ANXA5 as a clinical stage marker. Methods According to the international FIGO methods, the carcinoma tissues were classified as stages Ⅰ, Ⅱ and Ⅲ. RT-PCR method was used to determine the ANXA5 mRNA expression; Western boltting method and immunohistochemistry were employed to determine the protein expression. Comparisons between any two groups were analyzed by t-test.Results According to RT-PCR, intensities for ANXA5 mRNA expression were lower at stage Ⅰ than at stages Ⅱ and Ⅲ（EM>P /EM><0.05）. According to Western blotting, a total amount of ANXA5 protein was Ⅰ lower at stage Ⅰ than at stages Ⅱ and Ⅲ（EM>P /EM><0.05）, whi

Key words: AnnexinA5, Clinical stage, Uterine cervical squamous carcinoma, Western blotting, Human